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Background: RasGAP and its stress-activated caspase-3-generated fragments N and N2 have the potential to regulate
receptor tyrosine kinase (RTK) signaling.
Results: RasGAP and fragment N favor FGF1-mediated signaling via different mechanisms, whereas fragment N2 blocks it.
Conclusion: Stress, via the cleavage of RasGAP, modulates RTK signaling.
Significance: This work provides a mechanistic framework of how stress impacts on cell signaling.
Fibroblast growth factor receptors (FGFRs) are involved
in proliferative and differentiation physiological responses.
Deregulation of FGFR-mediated signaling involving the Ras/
PI3K/Akt and the Ras/Raf/ERK MAPK pathways is causally
involved in the development of several cancers. The caspase-3/
p120 RasGAP module is a stress sensor switch. Under mild
stress conditions, RasGAP is cleaved by caspase-3 at position
455. The resulting N-terminal fragment, called fragment N,
stimulates anti-death signaling.When caspase-3 activity further
increases, fragment N is cleaved at position 157. This generates
a fragment, called N2, that no longer protects cells. Here, we
investigated in Xenopus oocytes the impact of RasGAP and its
fragments on FGF1-mediated signaling during G2/M cell cycle
transition. RasGAP used its N-terminal Src homology 2 domain
to bind FGFR once stimulated by FGF1, and this was necessary
for the recruitment of Akt to the FGFR complex. Fragment N,
which did not associate with the FGFR complex, favored
FGF1-induced ERK stimulation, leading to accelerated G2/M
transition. In contrast, fragment N2 bound the FGFR, and
this inhibited mTORC2-dependent Akt Ser-473 phosphory-
lation and ERK2 phosphorylation but not phosphorylation of
Akt on Thr-308. This also blocked cell cycle progression.
Inhibition of Akt Ser-473 phosphorylation and entry into
G2/M was relieved by PHLPP phosphatase inhibition. Hence,
full-length RasGAP favors Akt activity by shielding it from
deactivating phosphatases. This shielding was abrogated by
fragment N2. These results highlight the role played by Ras-
GAP in FGFR signaling and how graded stress intensities, by
generating different RasGAP fragments, can positively or
negatively impact this signaling.
The fibroblast growth factor (FGF) family comprises a large
number of members (up to 22) that regulate embryonic devel-
opment and, in adult life, control cell cycle, proliferation, dif-
ferentiation, migration, and survival (1–3). FGF binds to high
affinity transmembrane tyrosine kinase receptors (receptor
tyrosine kinases) called FGF receptors (FGFRs).3 The signaling
and biological responses elicited by FGF/FGFR are dictated by
their intracellular domain (4). FGFR deregulation is frequently
observed during cancer development and progression (5). Of
note, FGFR1 alterations or amplifications have been detected in
8–10% of breast cancers (6). FGFR1 is expressed by hormone-
independent breast cancer cells, such asMDA-MB-231 cells, in
which it provides an autocrine proliferative response character-
ized by a succession of anarchic cell cycles (7, 8, 10–12). More-
over, the activation of the FGFR pathways may provide the
means for resistance against available anti-cancer drugs and
ionizing radiations (6). Consequently, increasing efforts are
currently focusing on the development of strategies to target
FGF/FGFR signaling for cancer therapy.
FGF binding to FGFRs promotes their phosphorylation and
activation, which initiates various intracellular signaling path-
ways, including the PI3K/Akt and the Ras/ERK MAPK path-
ways (13). The recruitment and the activation of proteins impli-
cated in the PI3K/Akt signaling cascade occur in an ordered
sequence of events through the successive docking of FRS2,
Grb2, and PI3K to the autophosphorylated FGFR (4). PI3K acti-
vation leads to the recruitment of Akt to the plasmamembrane
through its pleckstrin homology (PH) domain, allowing Akt
phosphorylation on two key activating residues, Thr-308 and
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Ser-473 (14). The activation loop of Akt is phosphorylated on
Thr-308 by another FGFR-recruited kinase, PDK1, and on Ser-
473 by the mTORC2 complex (15). The phosphorylation of
Thr-308 is a prerequisite for kinase activation, whereas the
phosphorylation of Ser-473 seems to further increaseAkt activ-
ity. However, Akt-dependent responses can be activated in the
absence of Ser-473 phosphorylation (15). Akt further interacts
with other cell cycle partners and anti-apoptotic substrates to
promote cell survival. Akt is deregulated in a large variety of
cancers. Radiotherapy relapse has been associated with persis-
tent Akt phosphorylation (16, 17). The activation of the Ras/
ERK MAPK pathway is brought about by the recruitment of
FRS2, Grb2, and the Ras guanine nucleotide exchange factor
Sos to trigger cell cycle progression (13). Similar to Ras activa-
tors, the Ras modulator p120 RasGAP associates, through its
N-terminal part, with the phosphorylated FGFR (18–20). Once
recruited by the FGFR, RasGAP, via its C-terminal GTPase-
activating protein (GAP) domain, stimulates the intrinsic
GTPase activity of Ras and hence favors its deactivation. The
binding of RasGAP to the FGFR also results in its phosphory-
lation, and this provides potential docking sites for additional
signaling proteins (18, 21, 22). Regulation of Ras activity by
RasGAP is complex, however, because its N-terminal moiety
positively participates in Ras signaling (21, 23). Consistent with
a positive effect of RasGAP on Ras signaling is the observation
that RasGAP, downstream of FGFR activation, is a co-activator
of the Src kinase to stimulate the Ras/MAPK cascade and cell
cycle progression (24).
The p120 RasGAP protein was shown to be sequentially
cleaved at two cleavage sites by graded increases in caspase-3
activity (25–27). The first cleavage of RasGAP occurs at very
low caspase-3 activity, generating two fragments, including an
N-terminal fragment (amino acids 1–455), called fragment N,
that exerts a potent anti-apoptotic signal mediated by the acti-
vation of the Ras/PI3K/Akt pathway (22, 27, 28). However, the
manner in which fragment N activates this pathway remains
poorly understood. The increase of caspase activity above a cer-
tain threshold leads to further cleavage of fragment N at posi-
tion 157 that generates two fragments called N1 (amino acids
1–156) and N2 (amino acids 157–455). The cleavage of frag-
ment N abrogates its capacity to activate Akt (29). This inacti-
vates the anti-apoptotic function of fragmentN so that caspases
are no longer hampered in their ability to kill cells (28). Frag-
ment N2 strongly potentiates cell death and sensitizes tumor
cells, but not normal cells, to the killing action of several geno-
toxins (30, 31). Fragment N2 also inhibits cell adhesiveness and
cell migration in a DLC1-dependent manner (32) as well as
hampering breast cancer metastatic progression (31). The
rationale for optimal targeting of the FGF/FGFR pathway in
cancers must incorporate the notion that the therapeutic treat-
ment needs to discriminate as much as possible between nor-
mal cells and tumor cells.
Studies on the regulation of cell division by growth factors
are sometimes difficult to interpret due to the other cellular
actions that these receptors exert. Biological systems where
specific FGFR responses on cell cycle can be analyzed are there-
fore useful to overcome this difficulty. The Xenopus oocyte has
long been used for this purpose (33–35). It offers the advantage
of a large cell in which specific growth factor receptors and
cytosolic regulators can be expressed and analyzed for signaling
using biochemical techniques. Xenopus oocytes express no
endogenous FGFR and only one tyrosine kinase receptor for
insulin. They are naturally arrested in the G2 phase of the cell
cycle. Their activation by the physiological inducer progester-
one, by insulin, or by ligands of heterologously expressed
growth factor receptors allows their synchronized progression
into the M phase of the cell cycle (also called the maturation
process) (36). Using this model, the signaling complexes and
the various cascades elicited by different FGFR isoforms and by
FGFR from breast cancer cells have been successfully charac-
terized (24, 37–39). In the present study, we used this powerful
integrated cellular system to investigate the impact of RasGAP
and its caspase-3-generated fragments on the signaling events
triggered by FGFR stimulation.
Experimental Procedures
Estrogen-independent Breast Cancer Cell Culture andOocyte
Handling—MDA-MB-231 cells were cultured at confluence in
a humidified atmosphere of 5% CO2 in Eagle’s medium con-
taining 10% fetal calf serum, 20 mM HEPES, 2 g/liter sodium
bicarbonate, 2 mM L-glutamine, 100 IU/ml penicillin, 100
g/ml streptomycin, 10 g/ml gentamycin sulfate. After anes-
thesia with MS 222 (1 g/liter; Sandoz), Xenopus laevis ovaries
were surgically removed and placed in ND96 medium (96 mM
NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES,
adjusted to pH 7.4withNaOH), supplementedwith streptomy-
cin/penicillin (50 g/ml; Eurobio), sodium pyruvate (225
g/ml; Sigma), and soybean trypsin inhibitor (30 g/ml;
Sigma). Stage VI oocytes were harvested by using a 1-h treat-
ment with collagenase A (1 mg/ml; Roche Applied Science)
followed by a manual defolliculation. The oocytes were kept at
19 °C in the ND96 medium. For each experiment, 20 oocytes
isolated from three animals were used.
Fusion Protein and RNA Preparations—Fragment N, frag-
ment N2, and glutathione S-transferase (GST) were produced
as described previously (26), using the corresponding bacterial
expression vectors, and purified as described (37). The RasGAP
SH2-SH3-SH2-GST and SH3-GST fusion proteins were gifts
from Dr. C. Garbay. Plasmids encoding GST-tagged SH2
domains of either RasGAP orGrb2 were a gift from Dr. S.
Courtneidge. Capped cRNAs were transcribed using the
mMessage mMachine kit (Ambion). Poly(A) mRNAs from
MDA-MB-231 cells were extracted by the guanidium thiocya-
nate/cesium chloride gradient method (40), using RNA plus
reagent from Bioprobe followed by poly(dT) columns (Amer-
sham Biosciences). The hormone-independent human mam-
mary MDA-MB-231 cell line, derived from a highly invasive
tumor, expresses FGFR1 and FGFR4 and several types of
FGFR1 splice variants (12, 42, 43).
Plasmids—HA-hRasGAP.dn3[118] is a eukaryotic expres-
sion vector encoding the N-terminally HA-tagged version of
human p120 RasGAP. It was described previously (44) as
HA-GAP.dn3.
GST-hRasGAP[158–455].pgx[205]) is a bacterial expression
vector encoding fragment N2 of RasGAP tagged at its N termi-
nus with GST. It was constructed by PCR-amplifying
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HA-hRasGAP[158–455].dn3[145], previously called HA-
N2.dn3 (44), with the sense oligo 239 (TTGGTT (feeder)
GGATCC (BamHI) TCTCTGGATGGACCAG (nucleotides
590–605 of human p120 RasGAP; NCBI entry M23379)) and
the antisense oligo 240 (ACACAC (feeder) GAATTC (EcoRI)
TCA (stop codon) ATCCACTGTGTCATTG (nucleotides
1483–1468 of human p120 RasGAP; NCBI entry M23379)).
The PCR fragment was cut with BamHI and EcoRI and sub-
cloned into pGEX-KG[88] (LGC Standards, Middlesex, UK)
opened with the same enzyme.
SjGST26.cmv[574] is a eukaryotic expression vector encod-
ing the Schistosoma japonicum class Mu 26-kDa GST isozyme
(GST26) (Uniprotenty: P08515, GST26_SCHJA).
GST-hRasGAP[158–455].cmv[907] is a eukaryotic expres-
sion vector coding for an N-terminally GST-tagged version of
human RasGAP fragment N2. It was generated by subcloning
the BamHI/XhoI insert of GST-hRasGAP[158–455].pgx[205]
into SjGST26.cmv[574] opened with the same enzyme.
GST-hRasGAP[1–455](D157A).pgx[234] is a prokaryotic
expression vector coding for an N-terminally GST-tagged ver-
sion of the caspase-3-resistant form of human RasGAP
fragment N. It was described previously (30) as N(D157A).pgx.
GST-hRasGAP[1–455](D157A).cmv[578] is a eukaryotic
expression vector coding for an N-terminally GST-tagged ver-
sion of the caspase-3-resistant form of human RasGAP
fragment N. It was produced by subcloning the BamHI/XhoI
insert of GST-hRasGAP[1–455](D157A).pgx[234] into the
SjGST26.cmv[574] plasmid opened with the same enzyme.
GST-hRasGGST-hRasGAP[1–119,146 – 455](D157A).
cmv[905] is a eukaryotic expression vector coding for an N-ter-
minally GST-tagged version of the caspase-3-resistant form of
human RasGAP fragment N lacking a polyproline-rich sequence
within its PP domain (120–145). It was constructed with the
QuikChange II XL mutagenesis kit (Agilent Technologies, Santa
Clara,CA)usingGST-hRasGAP[1–455](D157A).cmv[578] as the
template amplified with the sense oligo 1287 (nucleotides 459–
475 of human p120 RasGAP; NCBI entry M23379),
TTGGGGGCGGGC (nucleotides 554–565 of human p120 Ras-
GAP;NCBI entryM23379), and the antisense oligo 1288 (comple-
mentary sequence of oligo 1287).
GST-hRasGAP[1–455](D157A,W317D).cmv[906] is a
eukaryotic expression vector coding for an amino-terminally
GST-tagged version of the caspase-3-resistant form of human
RasGAP fragment N bearing an amino acid substitution
(W317D) expected to disrupt the capacity of its SH3 domain to
interact with its partners (45, 46). It was constructed with the
QuikChange II XL mutagenesis kit using GST-hRasGAP[1–
455](D157A).cmv[578] as the template amplified in separate
tubes with the sense oligo 1286 (G TTC ATT GTT CAT AAT
GAA TTA GAA GAT GGA GAT ATG TGG GTT ACA AAT
TTA AGA ACA GAT GAA C (nucleotides 1036–1100 of
human p120 RasGAP; NCBI entry M23379); the underlined
nucleotides correspond to the TGG to GATmutation convert-
ing the tryptophan residue at 317 into an aspartate residue) and
the antisense oligo 1285 (complementary sequence of oligo
1286). After 30 amplification cycles, the two PCRs were mixed,
denatured, and allowed to cool down slowly so that the two
mutated strands could anneal. The template DNA was then
digested with DpnI.
Microinjection, Drug Treatments, and Germinal Vesicle
Breakdown (GVBD) Analysis (G2/M Checkpoint Assay)—
Microinjection, in the equatorial region of the oocyte cyto-
plasm, of 60 ng of FGFR1, PDGF-FGFR1 (human chimeric
PDGF receptor extracellular domain coupled to FGFR1 intra-
cellular domain), or FGFR mRNAs from the breast cancer cell
line MDA-MB-231 was performed 48 h before the addition of
FGF1 to the extracellular medium (5 nM; R&D Systems, Abing-
don, UK) as described (37–39). Sixty ng of RasGAP SH2-SH3-
SH2, SH2 (Nter), or SH3 constructs of RasGAPor SH2domains
of Grb2, GST, or Nter HA-tagged RasGAP or 60 ng of each
anti-AktPHdomain (SKB1, Calbiochem), anti-PHLPP (Abcam,
Cambridge, UK), anti-Sin1 (Millipore), and anti-IgG (Santa
Cruz Biotechnology, Inc.) antibodies were injected 1 h before
the addition of FGF1. Extracellular medium incubation with
cycloheximide (15 M; Sigma) or staurosporine (Sigma) was
also performed 1 h before FGF1 treatment. Control oocytes
were microinjected into their cytoplasm with 60 nl of water
unless specified with 60 ng of GST. For insulin time course
experiments, 10 M was used to stimulate naive oocytes.
Nuclear microinjection with 20 ng of plasmid was realized in
oocytes expressing FGFR mRNAs from the breast cancer
MDA-MB-231 cells for 36 h, and stimulation with FGF1 was
performed 18 h after. In all cases, GVBD, a surrogate of oocyte
cell cycle progression fromG2 toM,was assessed by the appear-
ance of a white spot at the animal pole.
Immunoprecipitations of FGFR, Insulin Receptor, and
RasGAP—Oocytes expressing FGFR1, PDGF-FGFR1 (a chime-
ric FGFR1 receptor composed of the extracellular part of the
human PDGF receptor and the intracellular part of the human
FGFR1 receptor), or FGFR(MDA) (FGFR derived from the
estrogen-independent breast cancer cell line MDA-MB-231)
for 48 h were microinjected with various fusion proteins (Ras-
GAP SH2-SH3-SH2-GST, RasGAP SH2-GST, Grb2-SH2-
GST, RasGAP SH3-GST, GST) or antibodies (anti-PHLPP
(Abcam, UK), anti-Sin1 (Millipore), anti-Akt PH domain
(SKB1, Calbiochem), anti-IgG (Santa Cruz Biotechnology)) for
1 h, before stimulation by FGF1 or PDGF. Both of these oocytes
andMDA-MB-231 cells were lysed in 200l of buffer A (25mM
MOPS, pH-adjusted to 7.2, 60 mM  glycerophosphate, 15 mM
para-nitrophenyl phosphate, 15 mM EDTA, 15 mM MgCl2, 2
mM DTT, 1 mM ortho-sodium vanadate, 1 mM NaF, 1 mM phe-
nylphosphate, 10 g/ml leupeptin, 10 g/ml aprotinin, 10
g/ml soybean trypsin inhibitor, 10M benzamidine). Extracts
were centrifuged at 4 °C for 15min at 10,000 g. Some samples
were directly used as total cell fraction and submitted toWest-
ern blot analysis. Cytosolic fractionswere separated frommem-
brane pellets that were resuspended and mechanically homog-
enized with a pestle at 4 °C in buffer A containing 1% Triton
X-100 and then centrifuged under the same conditions. For
competition experiments on MDA-MB-231 cell extracts, Ras-
GAP SH2-SH3-SH2-GST andGrb2-SH2were added 1 h before
immunoprecipitation was performed. For immunoprecipita-
tions, supernatants were precleared with protein A-Sepharose
(50%; Sigma) for 1 h at 4 °C before the addition of anti-FGFR
antibodies (anti-FGFR1; Upstate Biotechnology) or anti-Ras-
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GAP (Santa Cruz Biotechnology) for 2 h. Immunocomplexes
were pulled down using protein A-Sepharose (50%; Sigma) for
1 h at 4 °C, rinsed three times, resuspended in Laemmli sample
buffer, and subjected to SDS-PAGE analysis. For insulin recep-
tor immunoprecipitations, the same protocol was applied on
naive oocytes using anti-insulin receptor (gift from Prof. D.
Boujard, Université de Rennes) and anti-insulin-like growth
factor receptor (Cell Signaling) antibodies.
RasActivity—Oocytes, expressing FGFR1 for 48 h andmicro-
injected with various fusion proteins (RasGAP SH2-SH3-SH2-
GST and N and N2 RasGAP) 1 h before stimulation by FGF1,
were lysed in 200l of buffer A. Total extracts were centrifuged
at 4 °C for 15min at 10,000 g to remove vitelline platelets. For
membrane fractions, cytosols were discarded, and membranes
were resuspended andmechanically homogenizedwith a pestle
at 4 °C in buffer A containing 1% Triton X-100 and then centri-
fuged under the same conditions. Active Ras was determined
using a Ras activation assay kit (Upstate Biotechnology) as per
the manufacturer’s instructions. This kit uses the Raf1 Ras-
binding domain to pull down RasGTP and an anti-pan-Ras
antibody to reveal the immobilized fraction of active Ras on
Western blot.
Electrophoresis, Western Blot Analysis, and Stripping—Sam-
pleswere resuspended in Laemmli buffer and subjected to SDS-
PAGE electrophoresis and transferred to a Hybond ECL mem-
brane (Amersham Biosciences) in Tris/NaCl/Tween/BSA, pH
8 (15 mM Tris-HCl, 150 mM NaCl, 0.1% Tween, 10% bovine
serum albumin; Sigma). The membranes were immunor-
evealed with the following antibodies: anti-FGFR1 antibodies
(clone 19B2, Upstate Biotechnology), anti-RasGAP (171, Santa
Cruz Biotechnology), anti-Akt (sc1618, Santa Cruz Biotechnol-
ogy), anti-phospho-Akt (Ser-473, Upstate Biotechnology; Thr-
308, New England Biolabs), anti-ERK2 (D2, Santa Cruz Bio-
technology), anti-phospho-ERK2 (Santa Cruz Biotechnology),
anti-Grb2 (Santa Cruz Biotechnology), anti-Mos (Santa Cruz
Biotechnology), anti-caspase 3 (BD Biosciences), anti-HA
(Santa Cruz Biotechnology), anti-Aurora A (Santa Cruz Bio-
technology), anti-phospho-Aurora A (Transduction Laborato-
ries), and anti-GST (gift from Dr. C. Dissous). Detection of the
immunocomplexes was performed with the advanced ECL
detection system (Amersham Biosciences). Before they were
reprobed, Western blots were treated with antibody stripping
buffer from (Gene Bio-Application Ltd.) using instructions
from the manufacturer.
Results
The RasGAP N and N2 Fragments Differentially Affect the
Akt and ERK2 FGFR-mediated Signaling Pathways—To deci-
pher the role played by fragment N and fragment N2 (see Fig. 1
for a schematic representation of the RasGAP-derived con-
structs used in this study) in proximal FGFR signaling, activa-
tion of the Akt and ERK2 MAPK pathways was analyzed over
time after FGFR stimulation. We initially used the wild-type
FGFR1 and FGFRs derived from the estrogen-independent
breast cancer cell lineMDA-MB-231 (37), hereafter referred to
as FGFR(MDA), to perform these experiments. The rationale to
do so was to gather information on the signaling deregulations
that can occur in breast cancers. Fig. 2A (top blots) shows that
fragment N and fragment N2 did not activate Akt or the ERK
MAPK pathways on their own. However, upon FGF1 stimula-
tion, fragment N induced an earlier phosphorylation of ERK2,
both in wild-type FGFR- and in FGFR(MDA)-expressing
oocytes (Fig. 2A). On the other hand, fragment N did not mod-
ulate FGF1- or insulin-mediated Akt activation (Fig. 2A).
Fragment N was also able to accelerate insulin-mediated ERK2
phosphorylation and G2/M transition (Fig. 2A), suggesting that
fragmentN does not need to engage a specific receptor tyrosine
kinase to exert this effect. FragmentN2, in contrast to fragment
N, potently inhibited ERK activation, G2/M transition, and the
phosphorylation of Akt on serine 473 (but not on threonine
308) (Fig. 2A). This effect was specific to FGF1 signaling
because it was not observedwhen oocytes were stimulated with
insulin (Fig. 2A). A fragment slightly shorter than fragment N2,
called SH2-SH3-SH2 (amino acids 170–440), also blockedERK
activation, G2/M transition, and phosphorylation of Akt on res-
idue 473 (Fig. 2B) (24). The SH3 domain of RasGAP (amino
acids 279–341) blocked ERK2phosphorylation andG2/M tran-
sition triggered by FGF1 but had no effect on Akt phosphory-
lation (Fig. 2B). Because the signaling behavior of the wild-type
FGFR1 and FGFR(MDA) receptors in the presence or in the
absence of RasGAP-derived fragments was identical (Fig. 2A),
we generally used only one of these FGFR receptor subtypes
(the receptors from MDA-MB-231 cells) in subsequent
experiments.
Sequential cleavage of RasGAP in the presence of graded
concentrations of active caspase-3 generates fragment N and
then fragments N1 and N2 (44). The results presented in Fig. 2,
A and B, predict that caspase-induced cleavage of RasGAP
mediated by increasing stress conditions should result in inhi-
bition of Akt phosphorylation on residue 473, ERK activation,
and G2/M progression when fragment N2 is produced but not
when fragmentN is generated. To test this hypothesis, a version
of full-length RasGAP HA-tagged fused at its N terminus was
injected into oocytes. The oocytes were then subjected to
graded concentrations of staurosporine, which generated
increasing activation of caspase-3 and a sequential cleavage of
FIGURE 1. RasGAP, fragment N, fragment N2, and the closely related
SH2-SH3-SH2 construct used in the study. The p120 RasGAP protein,
encoded by the Rasa1 gene, is a GAP specific for Ras that bears, from the
N-terminal end to the C-terminal end, a PP-rich domain, an SH3 domain
flanked by two SH2 domains, a PH domain, a C2 domain, and the GAP
domain. RasGAP displays two cleavage sites that are used sequentially as
caspase-3 (C3) activity increases. RasGAP is cleaved at low caspase-3 activ-
ity at site 1 (after amino acid 455). This generates an N-terminal product
called fragment N. At higher caspase-3 activity, fragment N is further
cleaved at site 2 (after amino acid 157), and this generates fragment N2.
SH2-SH3-SH2, used in previous experiments by some authors (18), corre-
sponds to a fragment that is slightly shorter than fragment N2. The
domains and the fragments are drawn to scale.
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RasGAP (Fig. 2C). The oocytes were finally stimulated with
FGF to induce G2/M transition. Fragment N was produced at
low caspase-3 activity, and this fragment was further cleaved
into fragments N1 and N2 at high caspase-3 activity (because
fragment N2 does not bear the HA tag, only fragment N1 is
detected in the blot shown). Low concentration staurosporine-
induced fragmentN production did not hamperAkt phosphor-
ylation, ERK activation, or G2/M transition, but further cleav-
age of fragment N into fragments N1 and N2 at higher
staurosporine concentrations did. The benzyloxycarbonyl-
VAD caspase inhibitor blocked RasGAP processing and fully
prevented high staurosporine concentration-induced inhibi-
tion of G2/M transition andAkt and ERK phosphorylation (Fig.
2C). These results are compatible with the notion that stress-
induced caspase-mediated cleavage of RasGAP differentially
modulates FGF receptor signaling in amanner that depends on
the extent of RasGAP processing.
Role of Translation in the Signaling-inhibitory Functions of
RasGAP Fragments—The cycloheximide translation inhibitor
mimicked the capacity of the SH3 domain of RasGAP to inhibit
FGF1-induced ERK activation and G2/M transition (Fig. 3A).
This suggests that this SH3 domain blocks the expression of
proteins (e.g. Mos; see Fig. 11) required for subsequent ERK
activation and G2/M transition. Fig. 3A also shows that frag-
ment N2 does not require new protein synthesis to block Akt
phosphorylation on Ser-473 because this was unaffected by
cycloheximide.
Synchronized FGF-mediated Signaling in Xenopus Oocytes—
The data presented so far indicate that there is a sharp activa-
tion of Akt upon FGF1 stimulation of FGF receptor-expressing
oocytes. To more precisely map the timing of Akt and ERK
stimulation by FGF1, we repeated the time course analyses of
activation of these proteins. Fig. 3, B and C, shows that there is
a synchronized and apparently maximal activation of Akt and
FIGURE2.Signalingcascadesactivatedby insulinandFGF receptorsaredifferentially regulatedbyRasGAP fragments.A, GST-taggedRasGAP fragment
N or N2 wasmicroinjected into naive oocytes or into oocytes where FGF receptors, either from the breast cancer cells MDA-MB-231 (FGFR(MDA)) or wild type
FGFR1, had been expressed for 48 h. Insulin receptors, naturally expressed in naive oocytes, were then stimulated by 10 M insulin, while FGF receptors were
stimulated with 5 nM FGF1. Extracts were prepared at the indicated times following FGF1 stimulation and analyzed by Western blotting using the indicated
antibodies. B, GST-tagged RasGAP SH2-SH3-SH2 or its SH3 domainwasmicroinjected into oocytes expressing FGFR(MDA) and then stimulatedwith 5 nM FGF1
and analyzed as inA. In conditionswhere no signals are detected, positive controls (FGF(MDA) receptors stimulatedwith FGF1 for 18 h) are included (indicated
by asterisks). C, a plasmid encoding the HA-tagged RasGAP was injected into oocytes 36 h after FGFR(MDA) mRNA. Oocytes were treated or not for 1 h with
benzyloxycarbonyl-VAD (ZVAD) and then submitted to gradually increasing concentrations of staurosporine for 1 h before stimulation with FGF1. The G2/M
progressionwas assessed as described. Total proteinswere extracted and subjected to SDS-PAGE andWestern blot analysis. The G2/M transitionwas assessed
by the appearance of a GVBD at the animal pole.
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ERKmediated by FGF1occurring between 25 and 30min and at
around 4 h, respectively. Hence, both proteins undergo very
precisely timed apparentlymaximal phosphorylationmodifica-
tions in growth factor-stimulated Xenopus oocytes.
Akt Binding to the FGFR-RasGAP Complex Is Disrupted by
the RasGAP-derived N2 and SH2 Fragments—We next ana-
lyzed the formation of signaling complexes on FGF receptors.
In oocytes expressing FGFR(MDA), immunoprecipitation
experiments using anti-FGFR antibodies revealed that RasGAP
and Grb2 were recruited to the FGFR 15 min after ligand addi-
tion. This was followed by Akt recruitment 15 min later (Fig.
4A). The differential recruitment of RasGAP, Grb2, and Akt to
the FGFR was also observed when RasGAP was immunopre-
cipitated from membrane fractions (Fig. 4B). The cytosolic
pools of Akt and RasGAP were fully recruited to the FGFR
signaling complex upon ligand stimulation (Fig. 4, C and D).
Similar results were observed in oocytes expressing wild-type
FGFR1 (data not shown). In contrast, neither RasGAP nor Akt
could be detected in insulin receptor immunoprecipitates upon
insulin stimulation (Fig. 5A).
When the SH2-SH3-SH2 fragment (a fragment N2-like con-
struct; see Fig. 1 and 2) or the first SH2 domain of RasGAP
(SH2(1)) was microinjected into FGFR(MDA)-expressing
oocytes, it fully competed with endogenous RasGAP for bind-
ing to the FGF receptors. This also prevented Akt recruitment,
but not Grb2 recruitment, to the FGFR complex (Fig. 4, A and
B). These RasGAP fragments exerted a similar effect in MDA-
MB-231 breast cancer cell extracts (Fig. 4E). These results indi-
cate that Grb2 can be recruited to FGFR complexes indepen-
dently of RasGAP (i.e. in conditions where RasGAP does not
bind to FGFR due to competition with smaller fragments). As a
control, Grb2 recruitment to the FGFR complex was abolished
by overexpression of the SH2 domain of Grb2 (Fig. 4, A and B).
Alone, the SH3 domain of RasGAP was unable to prevent Ras-
GAP and Akt recruitment to the FGFR complex (Fig. 6A).
Although the SH2-SH3-SH2 and (SH2(1)) constructs pre-
vented Akt from being recruited to the FGFR complex, they did
not inhibit Akt membrane translocation after FGFR signaling
was triggered by FGF1 addition (Fig. 4C). As expected, the
membrane translocation of Akt was prevented by injection of
an antibody directed against the Akt PH domain (Fig. 6).
The results presented above indicate that fragment N2 and
the nearly identical SH2-SH3-SH2 fragment bind to the FGFR
once stimulated. Surprisingly, fragment N, which contains the
SH2-SH3-SH2 domains, was unable to be recruited to the
FGFR complex and hence was unable to compete with endog-
enous RasGAP and Akt (Fig. 5, B and C). One possibility to
explain this finding is that the putative intramolecular interac-
tion between the SH3 domain and the polyproline (PP)-rich
domain of fragmentN affects the conformation of the fragment
so that it cannot interact with the FGF receptor complex. To
disrupt such putative intramolecular interaction, a mutation of
the SH3 domain known to prevent its interaction with PP
domains (45, 46) was introduced in fragmentN. Alternatively, a
25-amino acid stretch within the PP domain of fragment Nwas
deleted. Fig. 7B shows that both mutants, in contrast to wild-
type fragment N, were recruited to stimulated FGF receptors.
This occurred at the expense of Akt and full-length RasGAP
recruitment to the FGF receptor, resulting in the inhibition of
Akt phosphorylation at position 473 and blockage of the G2/M
transition (Fig. 7A). Hence, abrogating the putative intramolec-
ular interaction between the SH3 and PP domains of fragment
N made it behave as fragment N2 in terms of its capacity to be
recruited to the FGF receptor. Intriguingly, the W317D SH3
mutation, but not the PPmutation, prevented the FGF receptor
recruited fragment N to inhibit ERK activation. It is therefore
possible that a functional SH3 domainwithin fragmentN orN2
is necessary to exert a repressive activity on theMos/ERK path-
way (see Fig. 12). However, theW317D fragmentNmutant was
still able to block G2/M transition (Fig. 7A), suggesting that it
acted downstream of ERK to block G2/M transition. Addition-
ally, despite the fact that it bears the functional SH3 and PP
domains, full-length RasGAP is recruited to the activated FGF
receptor complex, and it does not inhibit G2/M transition.
Thus, there is obviouslymore complexity in the signaling of the
RasGAP-derived fragments than depicted in the model shown
in Fig. 12.
Modulation of Ras ActivationUpstream of ERK2 Phosphoryl-
ation in Cells Expressing Fragment N and Fragment N2—Ras
activity was detected in oocytes expressing FGFR(MDA) fol-
lowing FGF1 activation. This activity was increased upon injec-
tion of fragment N in the cytosol of oocytes starting at 30 min
and reaching amaximal level at 18 h post-stimulation (Fig. 8A).
Fragment N also induced a similar increase of Ras activity in
oocytes stimulatedwith insulin (Fig. 8B). FragmentN2 (and the
FIGURE 3. Protein synthesis requirement for Akt and ERK phosphoryla-
tion and kinetics of these responses. A, oocytes expressing FGFR(MDA) for
48 h were microinjected or not with fragment N or fragment N2 and then
treatedwith cycloheximide (15M) for 1hbefore stimulationwith FGF1. Total
cellular extracts were collected after 15 min, 30 min, 1 h, 4 h, and 18 h; SDS-
PAGE and Western blot analysis and G2/M cell cycle progression were per-
formed as described. In conditions where no signals are detected, positive
controls (FGF(MDA) receptors stimulated with FGF1 for 18 h) are included
(indicated by asterisks). The G2/M transition was assessed by the appearance
of a GVBD at the animal pole. B and C, oocytes where FGFR(MDA) had been
expressed for 48hwere stimulatedwith5nMFGF1.A timecourse analysiswas
performed after FGF1 addition at early time points (0–60 min) for Akt phos-
phorylation (B) or later time points (2–5.5 h) for ERK2 phosphorylation (C).
Total proteins were extracted and subjected to SDS-PAGE and Western blot
analysis.
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SH2-SH3-SH2 construct) did not affect Ras activity at the 30
min time point but totally suppressed Ras activity 18 h post-
stimulation (Fig. 8A). However, none of these constructs were
able to inhibit Ras activity induced by insulin (Fig. 8B). Levels of
Ras protein stayed constant regardless of the fragments
expressed or length of stimulation, suggesting that these frag-
ments modulate Ras activity at the post-transcriptional level.
The PHLPP Phosphatase Dephosphorylates Akt at Position
Ser-473 in Cells Expressing the RasGAP SH2-SH3-SH2
Domains—An anti-PHLPP antibody directed against active
PHLPP phosphatase, one of the major phosphatases able to
dephosphorylate Akt on serine 473 (39), wasmicroinjected into
oocytes expressing FGFR(MDA) (Fig. 9, A and B) or a chimeric
FGFR receptor composed by the extracellular part of the
human PDGF receptor and the intracellular part of the human
FGFR1 receptor (Fig. 9C), 1 h before stimulation by PDGF or
FGF1. This chimera, originally used to access the role played by
the intracellular domain versus the extracellular domain
(involvement of extracellular cofactor, such as low affinity hep-
arin sulfates), triggers similar signaling pathways as wild-type
FGFR1 (33). As a positive control for an antibody that could
disrupt a signal leading to Akt phosphorylation, we used an
antibody directed against Sin1, a component of the mTORC2
complex that phosphorylates Akt on serine 473. Injection of the
anti-PHLPP antibody led to an earlier FGF1-stimulated phos-
phorylation of Akt Ser-473 but did not affect Akt phosphoryla-
tion on Thr-308. As expected, the anti-Sin1 antibody blocked
Akt Ser-473, but not Akt Thr-308, phosphorylation (Fig. 9A).
When the SH2-SH3-SH2 construct was co-injected with the
anti-PHLPP antibody, Akt Ser-473 phosphorylation was
restored (Fig. 9, B and C, lane 6). This restored phosphoryla-
tion was mediated by mTORC2 because it was prevented by
the anti-Sin1 antibody (Fig. 9, B and C, lane 8). Phosphory-
lation of Akt on serine 473 upon injection of the anti-PHLPP
antibody concerned Akt molecules that were membrane-
bound but that were not associated with FGFR complexes
(Fig. 9B, part 2). The regulation of Akt phosphorylation
exerted by the RasGAP fragment was signal-specific because
the SH2-SH3-SH2 construct did not alter the extent of insu-
FIGURE4.RasGAPusesSH2domains tobindFGF1-stimulatedFGFR.A–D, oocytes expressing FGFR(MDA)weremicroinjectedwithorwithout the following
constructs: GST, GST-tagged SH2 domain of Grb2, or one of the following GST-tagged fragments of RasGAP: SH2-SH3-SH2 or SH2(1). A time course was
performed after FGF1 stimulation (15min, 30min, 1 h, 4 h, and 18h). E, MDA-MB-231 cell extractswere stimulatedor notwith FGF1 for 18 h and then submitted
for 1 h to various constructs. Immunoprecipitations (IP) were performedwith anti-FGFR (A and E) or anti-RasGAP antibodies (B). Wholemembrane extracts (C)
or whole cytosolic fractions (D) were analyzed by SDS-PAGE andWestern blotting using the indicated antibodies. In conditions where no signals are detected,
positive controls (FGF(MDA) receptors stimulated with FGF1 for 18 h) are included (indicated by asterisks).
FIGURE 5. Full-length RasGAP, but not fragment N, is recruited in FGFR
complexes. A, naive oocytes that naturally express the insulin receptor (A,
lanes on the vertical line) and oocytes expressing FGFR(MDA) for 48 h (A (lane
on the right of the vertical line), B, and C) were stimulated with 10 M insulin
and 15 nM FGF1, respectively. Thereafter, they were injected (B and C) or not
(A) with fragment N. Then the samples were collected at the indicated times
(A) or 18h later (BandC). Followingextraction, the sampleswere submitted to
immunoprecipitation (IP) as indicated (A and B) or separated intomembrane
and cytosolic fractions (C). The samples were finally analyzed by Western
blotting using the indicated antibodies. In the conditionwhere no signal was
detected, a positive control (GST) is included (indicated by the asterisk).
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lin-mediated, Sin1-dependent, Akt phosphorylation on res-
idues 473 and 308 (Fig. 10).
Impact of RasGAP Constructs on Aurora (Eg2) Regulation by
FGF—The first step in the activation of the MAPK pathway in
stimulated oocytes isMos synthesis (38), which was completely
abrogated by fragment N2, SH2-SH3-SH2, or the SH3 domain
(Fig. 11A). Efficient translation of Mos (47) requires phosphor-
ylation of Aurora kinase A (Eg2) (48). We observed that frag-
ments N2 and SH2-SH3-SH2 did indeed block Eg2 phosphor-
ylation (Fig. 11B). Therefore, the inhibitory RasGAP fragments
act upstream of Eg2 to modulate ERK2 activation and G2/M
transition.
Discussion
The investigation of the impact of fragments and domains of
RasGAP on FGFR complex composition performed in the pres-
ent work provides important information on the function of
RasGAP during FGF1 signaling as well as the signaling proper-
ties of the caspase-3-generated N and N2 fragments. Fig. 12
summarizes schematically the main findings of our study. Ras-
GAPwas recruited to the FGFR complexwith the same kinetics
as the adapter Grb2 (15 min after FGF1 stimulation), although
it did not depend on the presence of Grb2. Binding between
RasGAP and Akt has been reported (49), and indeed after Ras-
GAP recruitment, Akt was also recruited from the cytosol into
the FGFR complex. Fragment N was targeted to membranes;
however, this fragment, presumably because of an intermolec-
ular association between its SH3 and PP domains, could neither
associate with the FGFR complex after activation by FGF1 nor
displace full-length RasGAP or Akt from FGFR complexes.
In contrast, fragment N2 was able to displace RasGAP from
the FGFR complex. It also inhibited Akt incorporation into the
complex, although Akt remained membrane-bound. Blocking
the PH domain of Akt prevented the incorporation of Akt, but
not of RasGAP, into the FGFR complex. These results suggest
that it is RasGAP that recruits Akt into the FGFR complex and
not the other way around.
Phosphorylation of both ERK2 and Akt was induced after
stimulationwith insulin or FGF1. This phosphorylation pattern
was differently affected by fragment N or fragment N2. Akt
phosphorylation on the PDK1 site (threonine 308) was unaf-
fected by the RasGAP fragments. Phosphorylation of Akt on
serine 473, the site used by the mTORC2 complex, also
remained unaffected by fragment N. On the contrary, fragment
N2-like constructs or the first SH2 domain were found to
potently inhibit FGF1-stimulated, but not insulin-mediated,
phosphorylation of Akt on serine 473. Akt phosphorylation on
both the 473 and 308 sites was reported to be critical for Akt
activity (50). Although Akt phosphorylation on Thr-308 alone
may be sufficient to activate Akt in some instances (51, 52),
stronger Akt activity can be generated by additional phosphor-
ylation on Ser-473 (14) and possibly other sites (53). In our
heterologous system, however, Akt phosphorylation on serine
473 appears dispensable for the proliferative response down-
stream of FGFR activation because inhibition of FGF1-stimu-
lated Akt Ser-473 phosphorylation with anti-Sin1 antibodies
did not result in the blockage of G2/M transition.
Fragment N was found to accelerate by 3 h 30 min ERK2
phosphorylation induced by FGF1 or insulin. This fragment
does not need to be incorporated in receptor tyrosine kinase
signaling complexes to exert its effects because it is not
recruited in the FGFR complex (Fig. 5, B and C). However, it
was targeted to membranes, where it can obviously regulate
signaling originating from cell surface receptors. Fragment N
accelerated ERK2 phosphorylation in cells stimulated with
either insulin or FGF, suggesting that it did not directly act
through the FGFR complex tomodulate downstream signaling.
Together, these observations strongly suggest that fragment N
acts on activated signaling effectors that are not in the receptor
tyrosine kinase complexes themselves but instead downstream
in the signaling cascade. Ras is a good candidate in this context
because its activity is positively modulated by fragment N dur-
ing both FGFR and insulin signaling. The accelerated ERK2
phosphorylation led to an earlier G2/M transition in the oocyte
system. Surprisingly, Mos synthesis, an upstream event
involved in ERK2 phosphorylation and G2/M transition (24,
54), was delayed (Fig. 11). We have no explanation at the pres-
ent time for this discrepancy.
In stark contrast to fragment N, fragment N2 hastened Ras
inactivation following FGFR stimulation, impairing ERK2
phosphorylation and the G2/M transition. The effects of frag-
ment N2 were specific to FGFR signaling because it did not
FIGURE 6. Inhibition of Akt recruitment to the plasma membrane and
expression of individual RasGAP SH domains block FGF-mediated ERK2
phosphorylation. Oocytes expressing FGFR(MDA) for 48 h were treated as
described in the legend to Fig. 4. They were thenmicroinjected with or with-
out the indicated constructs or antibodies 1 h before being stimulated () or
not () with FGF1. Membrane and cytosolic extracts were immunoprecipi-
tated (IP) with anti-FGFR or anti-RasGAP antibodies and, together with non-
immunoprecipitated extracts, analyzed by Western blotting using the indi-
cated antibodies. In conditions where no signals are detected, positive
controls (FGF(MDA) receptors stimulated with FGF1 for 18 h) are included
(indicated by asterisks).
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impact insulin signaling. Fragment N2 most likely mediated its
effects by competing with endogenous full-length RasGAP,
avoiding its incorporation in the FGFR complex, whereas the
insulin receptor does not associate with RasGAP. Either frag-
ment N2 or the SH3 domain of RasGAP (but not full-length
RasGAP) blocked Mos protein synthesis and the activation of
its upstream activator Aurora kinase A, a prerequisite for
downstream ERK2 phosphorylation and activation in Xenopus
oocytes. It is unlikely that this is a consequence of its ability to
prevent Akt phosphorylation because Akt phosphorylation on
Ser-473 can be dissociated fromMos synthesis, ERK activation,
andG2/M transition. Rather, our data suggest that the ability of
fragment N2 to prevent G2/M transition most likely resides in
its capacity to inhibit targets upstream Aurora A (Eg2) phos-
phorylation,Mos synthesis, andERKactivation (38, 55). Aurora
A has been described as an interactor of the RasGAP SH3
domain, and it has been proposed to be inhibited by GSK3 (47,
56), which itself is inhibited by Akt. A hypothetical explanation
for the role of Akt could be that it acts as a positive regulator of
Aurora A and thus allows ERK2 phosphorylation. The simulta-
neous interaction of RasGAP with Akt and Aurora A, in the
context of the FGFR complex, could enhance such positive
regulation.
There have been conflicting reports regarding the interac-
tion betweenRasGAPandFGFR. RasGAPhas been shown to be
present and tyrosine-phosphorylated in FGFR1 complexes in
Xenopus oocytes and embryos (20, 24). RasGAP is recruited by
activated FGFRs in Drosophila and regulates the signaling
intensity of the Ras and ERK MAPK pathways (19). The inter-
action of RasGAP with FGFR appears dependent on the N-ter-
minal SH2 domain of RasGAP because this domain is recruited
into the FGFR complex, where it interferes with the binding of
endogenous RasGAP. This was specific for this particular SH2
domain because the SH2 domain of Grb2, while being able to
block the binding of Grb2 to the FGFR complex, did not abro-
gate the RasGAP-FGFR interaction.We show here that a single
isolated RasGAP-derived SH2 domain is able to induce this
displacement; however, it remains to be resolved whether, in
the context of the whole N2 fragment, the displacement
depends on a single SH2 domain.
Displacement of RasGAP from the FGFR complex specifi-
cally impaired Akt Ser-473 phosphorylation. Therefore, it was
of interest to determine whether Akt domains could alter the
binding of one of the partners in the FGFR complex. The clas-
sical function of PH domains is to interact with phosphorylated
lipids in the membrane (57, 58). It is known that Akt can be
recruited to the plasma membrane upon receptor tyrosine
kinase activation (59), but whether the subsequent incorpora-
tion in signaling complexes such as the FGFR complex also
required the PH domain is currently not known. Our results
indicate that the PH domain of Akt is critical for the anchorage
of Akt to the RasGAP-FGFR complex and for the phosphoryla-
tion of Akt on residues 473 and 308.
An important finding of our study is that full-length RasGAP
facilitates Akt activation by shielding it, within a receptor tyro-
sine kinase signaling complex, from serine 473-targeted phos-
phatases. This was revealed through the use of RasGAP frag-
ments, such as N2, that competed with the full-length protein
for binding to the FGFR. FragmentN2prevented the phosphor-
ylation of Akt on serine 473 (the mTORC2 site) but not phos-
phorylation on threonine 308 (the PDK1 site). Several phospha-
FIGURE 7. Intramolecular PP and SH3 domains of fragment N inhibits recruitment to FGF receptor complexes. Twenty ng of plasmids coding for
GST-tagged fragment N, its polyproline N(120–145) and SH3 N(W317D) mutants, or fragment N2 were microinjected or not in the nucleus of oocytes
expressingFGFR(MDA) for 36hand stimulated laterwith FGF1 for 18h.A, oocyteswere scored forG2/M transition andprepared for SDS-PAGEandWesternblot
analysis using the indicated antibodies. B, wholemembrane extracts or whole cytosolic fractionswere immunoprecipitated (IP) with anti-FGFR antibodies and
analyzedbyWesternblottingusing the indicated antibodies. Non-immunoprecipitatedextractswere also analyzed for thepresenceofGST-tagged constructs.
In the condition where no signal was detected, a positive control (GST) is included (indicated by the asterisk). The G2/M transition was assessed by the
appearance of a GVBD at the animal pole.
FIGURE 8. Fragment N enhances FGF1-mediated Ras activity. Oocytes
expressing FGFR(MDA) for 48 h (A) or naive oocytes (B) were microinjected
with the indicatedRasGAP-derived fragments and then treated () or not ()
with (5mM FGF1 (A) or 10M insulin (B)). Total protein extractswere collected
30 min and 18 h post-stimulation. Total Ras and pulled down active Ras pro-
teins were visualized by Western blot.
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tases have been involved in Ser-473 dephosphorylation,
including the PHLPP phosphatase (60–62). The use of an anti-
body against PHLPP showed that mTORC2-dependent Akt
Ser-473 phosphorylation was preserved in FGF1-simulated
oocytes expressing fragment N2. This indicates that PHLPP
phosphatases are mediating the dephosphorylation of Akt on
serine 473 when full-length RasGAP is displaced. One possibil-
ity is that fragment N2 facilitates the action of PHLPP within
the FGFR complex. However, this does not seem to be the case
because fragment N2 disrupts the association of Akt with the
FGFR complex. Despite the fact that it does not associate with
the FGFR complex in the presence of fragment N2, Akt is nev-
ertheless targeted to membranes, where it can be phosphory-
lated by PDK1 upon FGF1 stimulation and by mTORC2, in the
latter case only when PHLPP is inhibited. It can therefore be
concluded that fragment N2 favors the dephosphorylation of
Akt on serine 473 by PHLPP by removing Akt from the protec-
tive RasGAP-dependent environment within the FGFR signal-
ing complex.
Our study also provides information on how the caspase-3-
generated RasGAP fragments modulate receptor tyrosine
kinase signaling, which can explain some of their respective
cellular functions. FragmentN is known to exert potent survival
functions that depend on the activation of the Ras/PI3K/Akt
pathway. Previous work has shown that fragment N expression
in mammalian cell lines leads to Ras and Akt stimulation (23,
26, 63). Using theXenopus oocyte, it was found that fragmentN
FIGURE 9. Anti-PHLPP antibodies abrogate fragment N2-mediated inhibition of Akt Ser-473 phosphorylation in oocytes expressing FGFR. A, anti-
PHLPP and anti-Sin1 antibodies were injected into oocytes expressing FGFR(MDA). They were then stimulated or not with 5 nM FGF1, and samples were
collected after 15 min, 30 min, 1 h, 4 h, and 18 h of treatment. B, anti-PHLPP and anti-Sin1 antibodies or SH2-SH3-SH2 RasGAP-GST were microinjected into
oocytes expressing FGFR(MDA) 1 h before stimulationwith 5 nM FGF1. C, oocytes expressing a chimeric FGFR1 receptor (composed of the extracellular part of
the human PDGF receptor and the intracellular part of the human FGFR1 receptor) were treated as in B and stimulated with 5 nM PDGF. Total cellular extracts
(A), FGF receptor-immunoprecipitated extracts (B1 and C1), whole membrane fractions (B2 and C2), and cytosolic fractions (B3 and C3) were analyzed by
Western blotting using the indicated antibodies. The G2/M transition was scored for each condition. In conditions where no signals are detected, positive
controls (FGF(MDA) receptors stimulated with FGF1 for 18 h) are included (indicated by asterisks). The G2/M transition was assessed by the appearance of a
GVBD at the animal pole.
FIGURE 10. The SH2-SH3-SH2 RasGAP fragment does not inhibit phos-
phorylation of Akt Ser-473 in insulin-stimulated oocytes. Naive oocytes
were microinjected with the SH2-SH3-SH2 construct of RasGAP alone and
together with the indicated combinations of anti-PHLPP and anti-Sin1 anti-
bodies. The oocytes were then stimulatedwith 10M insulin. Total extract (1)
andmembrane fractions (2) were analyzed byWestern blot alone or with the
indicated antibodies. The G2/M transition was assessed by the appearance of
a GVBD at the animal pole.
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alone could not activate Akt on its own. However, fragment N
strongly potentiated FGF1-induced Ras stimulation in terms of
intensity and more particularly so in terms of persistence.
Besides the possibility of a species-dependent specificity, this
could be related to the fact that oocytes are cell cycle-arrested,
whereas the mammalian cells used in previous studies are
tumor cells continuously proliferating, undergoing tonic acti-
vation of growth factor and/or oncogene-dependent signaling.
Based on the present finding, one could predict that inhibition
of those tonic signals would prevent fragment N from favoring
the activation of Akt in mammalian cells. Fragment N would
therefore be unable to protect cells that are not concomitantly
activating pathways that stimulate Akt to some extent.
Fragment N2 and fragment N2-derived peptides sensitize
tumor cells to anti-cancer drugs (28, 64–66), but the underly-
ing mechanisms remain obscure (67, 68). Here we show that
fragment N2 potently inhibits FGF1-induced phosphorylation
of ERK2 andAkt. Because bothAkt and ERK2 participate in cell
survival signaling (69), one possibility to explain the capacity of
fragmentN2 to sensitize tumor cells to anti-cancer treatment is
a shutdown of pro-survival pathways. There is, however, no
evidence for suchmechanisms inmammalian cells. Indeed, nei-
ther the ERK MAPK pathway nor Akt is modulated by the
tumor-sensitizing fragment N2-derived peptides in tumor cell
lines (41). Hence, although fragment N2 has the potential to
inhibit growth factor-mediated pro-survival signaling, as
shown here for FGF1, it is unlikely that this is the main mech-
anism underlying its broad anti-tumoral activity. Nevertheless,
because dysregulation in Akt signaling is found in a majority of
cancer (9), the use of a fragment N2-like compound could be
particularly useful to target RasGAP in receptor tyrosine kinase
signaling complex in order to render Akt accessible to inacti-
vating phosphatases.
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prevents PHLPP phosphatases from accessing Akt, which then becomes fully
activated as a result of its phosphorylationon Thr-308 (PDK1 site) and Ser-473
(mTORC2 site). Full-length RasGAP also mediates FGF1-induced Mos-depen-
dent ERK activation and cell cycle progression. Fragment N does not bind to
the FGFRbut contributes to Ras activation and ERK stimulation. The three thin
lines connecting the PP and the SH3 domains of fragment N indicate a puta-
tive cis interaction, whichwould affect the accessibility of its SH2 domains for
binding to FGF1 receptors.Bottom, fragmentN2binds to the FGFR, displacing
full-length RasGAP away from the FGFR complex. Akt is no longer shielded
from PHLPP phosphatases that now counteract phosphorylation on the
mTORC2 site. As a result, Akt activity is inhibited. FragmentN2 is blockingMos
signaling.
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